Advertisement

Uterine Cancer pp 387-395 | Cite as

Metabolic Syndrome and Endometrial Cancer

  • K. Chandramohan
  • P. M. Arun

Abstract

Metabolic syndrome (MetS) is a group of interrelated disorders, which increase the risk of cardiovascular disease and type 2 diabetes mellitus and is considered a worldwide epidemic by the International Diabetic Federation [1]. The components of MetS are dyslipidemia [characterized by an abnormal lipid profile such as high level triglyceride (TG) and low high density lipoprotein (HDL)], high arterial blood pressure, abnormal glucose metabolism, central adiposity, and insulin resistance. Recently other abnormalities such as chronic pro-inflammatory and pro-thrombotic states, fatty liver, and sleep apnea have been added to the syndrome [2].

Keywords

Insulin Resistance Metabolic Syndrome Waist Circumference Endometrial Cancer Endometrial Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Alberti KG, Zimmet P, Shaw J. Metabolic syndrome–a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23(5):469–80.PubMedCrossRefGoogle Scholar
  2. 2.
    Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9:48.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Nutrition. 1997;13(1):65; discussion 64, 66.PubMedGoogle Scholar
  4. 4.
    Mohan V, Sandeep S, Deepa M, Gokulakrishnan K, Datta M, Deepa R. A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians – the Chennai Urban Rural Epidemiology Study (CURES-38). Diabet Obes Metab. 2007;9(3):337–43.CrossRefGoogle Scholar
  5. 5.
    Parikh R, Mohan V, Joshi S. Should waist circumference be replaced by index of central obesity (ICO) in definition of metabolic syndrome? Diabet Metab Res Rev. 2012;28(1):3–5.CrossRefGoogle Scholar
  6. 6.
  7. 7.
    Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164(10):1066–76.PubMedCrossRefGoogle Scholar
  8. 8.
    Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27(10):2444–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.PubMedCrossRefGoogle Scholar
  10. 10.
    Cameron AJ, Boyko EJ, Sicree RA, Zimmet PZ, Soderberg S, Alberti KG, Tuomilehto J, Chitson P, Shaw JE. Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity (Silver Spring). 2008;16(12):2707–16.CrossRefGoogle Scholar
  11. 11.
    Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2010;375(9710):181–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Garaulet M, Madrid JA. Chronobiology, genetics and metabolic syndrome. Curr Opin Lipidol. 2009;20(2):127–34.PubMedCrossRefGoogle Scholar
  13. 13.
    Alberti KG, Zimmet P, Shaw J. The metabolic syndrome–a new worldwide definition. Lancet. 2005;366(9491):1059–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–97.CrossRefGoogle Scholar
  15. 15.
    Hillier TA, Fagot-Campagna A, Eschwege E, Vol S, Cailleau M, Balkau B. Weight change and changes in the metabolic syndrome as the French population moves towards overweight: the D.E.S.I.R. cohort. Int J Epidemiol. 2006;35(1):190–6.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    do Carmo I, Dos Santos O, Camolas J, Vieira J, Carreira M, Medina L, Reis L, Myatt J, Galvao-Teles A. Overweight and obesity in Portugal: national prevalence in 2003–2005. Obes Rev. 2008;9(1):11–9.PubMedGoogle Scholar
  17. 17.
    Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S9–30.PubMedCrossRefGoogle Scholar
  18. 18.
    Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol. 2006;169(5):1505–22.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11 [internet]. Lyon: International Agency for Research on Cancer. 2013. Available from: http://globocan.iarc.fr. Accessed 23 Dec 2014.
  20. 20.
    Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, Negri E, Franceschi S, La Vecchia C. Metabolic syndrome and endometrial cancer risk. Ann Oncol. 2011;22(4):884–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Wiseman M. The Second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc. 2008;67(3):253–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. Metabolic syndrome and endometrial cancer: a meta-analysis. 2014;45(1):28–36.Google Scholar
  23. 23.
    Bjorge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J, Rapp K, Ulmer H, Almquist M, Concin H, et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol. 2010;171(8):892–902.PubMedCrossRefGoogle Scholar
  24. 24.
    Nagel G, Concin H, Bjorge T, Rapp K, Manjer J, Hallmans G, Diem G, Haggstrom C, Engeland A, Almquist M, et al. Metabolic syndrome and rare gynecological cancers in the metabolic syndrome and cancer project (Me-Can). Ann Oncol. 2011;22(6):1339–45.PubMedCrossRefGoogle Scholar
  25. 25.
    Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Tjonneland A, Olsen A, Overvad K, Jakobsen MU, Chajes V, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European prospective investigation into cancer and nutrition (EPIC). Endocr Relat Cancer. 2007;14(3):755–67.PubMedCrossRefGoogle Scholar
  26. 26.
    Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, Anderson ML, Ramondetta LM, Tortolero-Luna G, Urbauer DL, et al. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol. 2011;204(4):355 e351–357.CrossRefGoogle Scholar
  27. 27.
    Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer. 2008;98(9):1582–5.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–18.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Bjorge T, Engeland A, Tretli S, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer. 2007;120(2):378–83.PubMedCrossRefGoogle Scholar
  30. 30.
    Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control. 2000;11(2):185–92.PubMedCrossRefGoogle Scholar
  31. 31.
    Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer. 2001;91(3):421–30.PubMedCrossRefGoogle Scholar
  32. 32.
    Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19(12):3119–30.PubMedCrossRefGoogle Scholar
  33. 33.
    Terry P, Baron JA, Weiderpass E, Yuen J, Lichtenstein P, Nyren O. Lifestyle and endometrial cancer risk: a cohort study from the Swedish twin registry. Int J Cancer. 1999;82(1):38–42.PubMedCrossRefGoogle Scholar
  34. 34.
    Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1531–43.PubMedGoogle Scholar
  35. 35.
    Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91.PubMedCrossRefGoogle Scholar
  36. 36.
    Park D, Pandey SK, Maksimova E, Kole S, Bernier M. Akt-dependent antiapoptotic action of insulin is sensitive to farnesyltransferase inhibitor. Biochemistry. 2000;39(41):12513–21.PubMedCrossRefGoogle Scholar
  37. 37.
    Straus DS. Growth-stimulatory actions of insulin in vitro and in vivo. Endocr Rev. 1984;5(2):356–69.PubMedCrossRefGoogle Scholar
  38. 38.
    Austin H, Austin Jr JM, Partridge EE, Hatch KD, Shingleton HM. Endometrial cancer, obesity, and body fat distribution. Cancer Res. 1991;51(2):568–72.PubMedGoogle Scholar
  39. 39.
    Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14(6):433–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Cust AE, Allen NE, Rinaldi S, Dossus L, Friedenreich C, Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, et al. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. Int J Cancer. 2007;120(12):2656–64.PubMedCrossRefGoogle Scholar
  41. 41.
    Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, Muti P, Lenner P, Koenig KL, Biessy C, et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP −1, −2 and −3 and risk of endometrial cancer. Int J Cancer. 2004;108(2):262–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Strasak AM, Pfeiffer RM, Brant LJ, Rapp K, Hilbe W, Oberaigner W, Lang S, Borena W, Concin H, Diem G, et al. Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women: a prospective 19-year follow-up study. Ann Oncol. 2009;20(6):1113–20.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci. 1999;24(2):68–72.PubMedCrossRefGoogle Scholar
  44. 44.
    Goldman NA, Katz EB, Glenn AS, Weldon RH, Jones JG, Lynch U, Fezzari MJ, Runowicz CD, Goldberg GL, Charron MJ. GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol. 2006;19(11):1429–36.PubMedGoogle Scholar
  45. 45.
    Shibata K, Kajiyama H, Ino K, Nawa A, Nomura S, Mizutani S, Kikkawa F. P-LAP/IRAP-induced cell proliferation and glucose uptake in endometrial carcinoma cells via insulin receptor signaling. BMC Cancer. 2007;7:15.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14.PubMedCrossRefGoogle Scholar
  47. 47.
    Parazzini F, La Vecchia C, Negri E, Riboldi GL, Surace M, Benzi G, Maina A, Chiaffarino F. Diabetes and endometrial cancer: an Italian case–control study. Int J Cancer. 1999;81(4):539–42.PubMedCrossRefGoogle Scholar
  48. 48.
    Murphy LJ. Growth factors and steroid hormone action in endometrial cancer. J Steroid Biochem Mol Biol. 1994;48(5–6):419–23.PubMedCrossRefGoogle Scholar
  49. 49.
    Irwin JC, Fuentes L, Dsupin BA, Giudice LC. Insulin-like growth factor regulation of human endometrial stromal cell function: coordinate effects on insulin-like growth factor binding protein-1, cell proliferation and prolactin secretion. Regul Pept. 1993;48(1–2):165–77.PubMedCrossRefGoogle Scholar
  50. 50.
    Weiderpass E, Brismar K, Bellocco R, Vainio H, Kaaks R. Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer. 2003;89(9):1697–704.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Thiet MP, Osathanondh R, Yeh J. Localization and timing of appearance of insulin, insulin-like growth factor-I, and their receptors in the human fetal mullerian tract. Am J Obstet Gynecol. 1994;170(1 Pt 1):152–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Nyholm H, Djursing H, Hagen C, Agner T, Bennett P, Svenstrup B. Androgens and estrogens in postmenopausal insulin-treated diabetic women. J Clin Endocrinol Metab. 1989;69(5):946–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Barbieri RL, Makris A, Ryan KJ. Effects of insulin on steroidogenesis in cultured porcine ovarian theca. Fertil Steril. 1983;40(2):237–41.PubMedGoogle Scholar
  54. 54.
    Kazer RR. Insulin resistance, insulin-like growth factor I and breast cancer: a hypothesis. Int J Cancer. 1995;62(4):403–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Cook L, Weiss N, Doherty JA, Chen C. Endometrial cancer, 3rd ed. New York. Women and Health Academic Press 2000Google Scholar
  56. 56.
    Corocleanu M. Hypothesis for endometrial carcinoma carcinogenesis. Preventive prospects. Clin Exp Obstet Gynecol. 1993;20(4):254–8.PubMedGoogle Scholar
  57. 57.
    Hamet P. Cancer and hypertension: a potential for crosstalk? J Hypertens. 1997;15(12 Pt 2):1573–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2001;15(3):341–54.PubMedCrossRefGoogle Scholar
  59. 59.
    Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension. 1999;34(2):320–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Hamet P. Cancer and hypertension. An unresolved issue. Hypertension. 1996;28(3):321–4.PubMedCrossRefGoogle Scholar
  61. 61.
    Giugliano D, Ceriello A, Esposito K. Are there specific treatments for the metabolic syndrome? Am J Clin Nutr. 2008;87(1):8–11.PubMedGoogle Scholar
  62. 62.
    Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114(1):82–96.PubMedCrossRefGoogle Scholar
  63. 63.
    Williams DE, Prevost AT, Whichelow MJ, Cox BD, Day NE, Wareham NJ. A cross-sectional study of dietary patterns with glucose intolerance and other features of the metabolic syndrome. Br J Nutr. 2000;83(3):257–66.PubMedCrossRefGoogle Scholar
  64. 64.
    Pereira MA, Jacobs Jr DR, Van Horn L, Slattery ML, Kartashov AI, Ludwig DS. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA study. JAMA. 2002;287(16):2081–9.PubMedCrossRefGoogle Scholar
  65. 65.
    McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PW, Jacques PF. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham offspring cohort. Diabetes Care. 2004;27(2):538–46.PubMedCrossRefGoogle Scholar
  66. 66.
    Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Tousoulis D, Toutouza M, Toutouzas P, Stefanadis C. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am Heart J. 2004;147(1):106–12.PubMedCrossRefGoogle Scholar
  67. 67.
    Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365(9468):1389–97.PubMedCrossRefGoogle Scholar
  68. 68.
    Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353(20):2121–34.PubMedCrossRefGoogle Scholar
  69. 69.
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295(7):761–75.PubMedCrossRefGoogle Scholar
  70. 70.
    Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142(8):611–9.PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation–implications for a novel treatment strategy. Gynecol Oncol. 2010;116(1):92–8.PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Esposito K, Ciotola M, Carleo D, Schisano B, Saccomanno F, Sasso FC, Cozzolino D, Assaloni R, Merante D, Ceriello A, et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care. 2006;29(5):1071–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Lee WJ, Huang MT, Wang W, Lin CM, Chen TC, Lai IR. Effects of obesity surgery on the metabolic syndrome. Arch Surg. 2004;139(10):1088–92.PubMedCrossRefGoogle Scholar
  74. 74.
    Vargas V, Allende H, Lecube A, Salcedo MT, Baena-Fustegueras JA, Fort JM, Rivero J, Ferrer R, Catalan R, Pardina E, et al. Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients. World J Hepatol. 2012;4(12):382–8.PubMedCentralPubMedGoogle Scholar
  75. 75.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–52.PubMedCrossRefGoogle Scholar
  76. 76.
    Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16(5):442–3.PubMedCrossRefGoogle Scholar
  77. 77.
    Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9(3):237–52.PubMedGoogle Scholar
  78. 78.
    Parikh RM, Mohan V. Changing definitions of metabolic syndrome. Indian J Endocrinol Metab. 2012;16(1):7–12.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer India 2015

Authors and Affiliations

  1. 1.Department of Surgical OncologyRegional Cancer CentreTrivandrumIndia

Personalised recommendations